Associate Vice President Virology and Analytical Methods Development
Fujifilms Diosynth Biotechnologies Texas
Steven Pincus obtained his B.S. and Ph.D.in Biochemistry from the State University of NY at Buffalo. His Ph.D. thesis project involved studies on the mechanism of Adenovirus DNA replication and he gained experience growing and purifying and tittering multiple Adenovirus serotypes. He obtained his post-doctoral training in the microbiology department at the State University of NY at Stony Brook under an NIH Fellowship studying inhibitors of picornavirus replication and gained experience in the growth and purification of and titration Poliovirus and growth of other picornaviruses. He then joined Virogenetics where he was Senior Scientist and Platform Leader in Molecular Biology and Microbiology.
He then joined Novavax, Inc., a biotech focusing on the development of vaccines against Influenza and Respiratory Syncytial Virus (RSV), based on Virus-Like Particle (VLP) platform vaccine technology. There he was responsible for analytical development, quality control and quality assurance, and recombinant baculovirus production. He was a key member of the team that secured a contract award valued at up to $179 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) for the advanced clinical and manufacturing development of recombinant vaccines for the prevention of seasonal and pandemic influenza. He has consulted for several companies in the areas of assay development, transfer, qualification and validation for monoclonal antibody and vaccine projects.